Immunicom, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immunicom, Inc. - overview
Established
2013
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Bases in California, US, and founded by Amir Jafri (CEO) in 2013, Immunicom, Inc. operates as a biotechnology company that develops orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. In September 2019, Immunicom, Inc. raised USD 1.
85 million, as part of a larger USD 12. 85 million Series B funding from various investors. The company went public on Nasdaq and trades under the ticker symbol IMUX. As of April 2023, the company is in clinical trials phase.
The company is working on a vidofludimus calcium (IMU-838) programme for the treatment of multiple sclerosis that selectively inhibits activated immune cells and has anti-inflammatory, antiviral, and neuroprotective effects. Another therapy being developed by the business, Izumerogant (IMU-935), is intended to help treat castration-resistant prostate cancer and psoriasis. The company is also creating and testing IMU-856, which aims to regenerate bowel epithelium and restore intestinal barrier function and is applicable to many gastrointestinal diseases, including celiac disease.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.immunicom.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.